- Home
- GDS vs MDGL Comparison
GDS vs MDGL Comparison
Compare GDS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDS
- MDGL
- Stock Information
- Founded
- GDS 2001
- MDGL 2011
- Country
- GDS China
- MDGL United States
- Employees
- GDS N/A
- MDGL N/A
- Industry
- GDS Computer Software: Programming Data Processing
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- GDS Technology
- MDGL Health Care
- Exchange
- GDS Nasdaq
- MDGL Nasdaq
- Market Cap
- GDS 6.7B
- MDGL 6.1B
- IPO Year
- GDS 2016
- MDGL N/A
- Fundamental
- Price
- GDS $36.55
- MDGL $420.32
- Analyst Decision
- GDS Strong Buy
- MDGL Strong Buy
- Analyst Count
- GDS 7
- MDGL 10
- Target Price
- GDS $47.51
- MDGL $474.67
- AVG Volume (30 Days)
- GDS 3.0M
- MDGL 383.6K
- Earning Date
- GDS 08-20-2025
- MDGL 10-30-2025
- Dividend Yield
- GDS N/A
- MDGL N/A
- EPS Growth
- GDS N/A
- MDGL N/A
- EPS
- GDS 3.46
- MDGL N/A
- Revenue
- GDS $1,526,241,101.00
- MDGL $515,547,000.00
- Revenue This Year
- GDS $13.51
- MDGL $394.12
- Revenue Next Year
- GDS $14.52
- MDGL $57.74
- P/E Ratio
- GDS $183.50
- MDGL N/A
- Revenue Growth
- GDS 10.29
- MDGL 3421.98
- 52 Week Low
- GDS $15.91
- MDGL $200.63
- 52 Week High
- GDS $52.50
- MDGL $457.16
- Technical
- Relative Strength Index (RSI)
- GDS 56.52
- MDGL 55.83
- Support Level
- GDS $32.96
- MDGL $425.00
- Resistance Level
- GDS $38.77
- MDGL $440.90
- Average True Range (ATR)
- GDS 1.66
- MDGL 14.10
- MACD
- GDS 0.46
- MDGL -4.40
- Stochastic Oscillator
- GDS 66.92
- MDGL 15.86
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia via the now 38% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.